医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

QIAGEN to deliver genomic insights for Japan’s new molecular oncology clinical research and precision medicine initiative

2019年06月19日 AM05:02
このエントリーをはてなブックマークに追加


 

HILDEN, Germany & TOKYO

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QIAGEN Clinical Insight (QCI) offering was selected by the National Cancer Center of Japan, as part of the Japan’s Ministry of Health, Labour and Welfare’s precision medicine program, for the analysis, interpretation and reporting of molecular oncology and oncogenetic screening of cancer patients to contribute to the identification of targeted therapy treatment and clinical trial options.

Japan’s Center for Cancer Genomics and Advanced Therapeutics (C-CAT), a unit within the National Cancer Center (NCC) of Japan, will use QIAGEN’s QCI platform including expert curated evidence knowledge bases, bioinformatics software and data center infrastructure to support the C-CAT’s molecular profiling services for core and cooperative hospitals of the country’s cancer genomic medicine program. QIAGEN has established an in-country data center in Tokyo, compliant with Japanese data security and privacy regulations, to support this national program.

QCI is a cloud-based clinical decision support software platform used to generate actionable insights from next-generation sequencing (NGS) data. QCI leverages QIAGEN’s expert manually curated evidence knowledge base that includes more than 10 million biomedical findings and thereby be far represents the world’s largest commercial database of curated evidence data on somatic and inherited genetic variants. QCI-Interpret minimizes the complexity and cost of determining the significance of NGS data and automates guidelines for clinical actionability from leading oncology and pathology organizations.

Please find the full press release here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190618006000/en/

CONTACT

QIAGEN
Investor Relations
John Gilardi, +49 2103
29 11711
Phoebe Loh, +49 2103 29 11457
e-mail: ir@QIAGEN.com

Public
Relations

Thomas Theuringer, +49 2103 29 11826
e-mail: pr@QIAGEN.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 複合細胞療法による尿道狭窄治療で特許を取得
  • Taiwan’s COVID-19 response win applause, friendship from around the world
  • EUSA Pharma宣布FDA核准Silvoximab治疗COVID-19相关急性呼吸窘迫综合征住院患者的3期临床试验
  • 治疗尿道狭窄的混合细胞疗法获得日本专利
  • 有力保健機関がハンドドライヤーの使用を推奨